Castrate-resistant Prostate Cancer Market

May 2021| MRS232A| Market Research Studies

Report Highlights

The report broadly covers different treatment types of castrate-resistant prostate cancer based on their drug delivery method. Furthermore, the scope of the report also covers the impact of COVID-19 and drivers and challenges for castrate-resistant prostate cancer market. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each treatment type, drug delivery method, end-user, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional castrate-resistant prostate cancer markets; it explains the major market drivers of the global castrate-resistant prostate cancer industry, current trends within the industry, major applications, and the regional dynamics of the global castrate-resistant prostate cancer market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the global castrate-resistant prostate cancer market.

Report Includes

  • 35 tables and 43 figures
  • An up-to-date analysis of the Global Castrate-resistant Prostate Cancer Market.
  • Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
  • Estimation of market size and revenue forecast for Global Castrate-resistant Prostate Cancer Market, and corresponding market share analysis by treatment type, drug delivery method, end-user, and region.
  • Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Castrate-resistant Prostate Cancer, identification of the companies that are best positioned to meet this demand.
  • In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
  • Identification of promising new products and therapies still in the development and testing stages, and their probability of successful commercial launch within the next five years
  • Impact of COVID-19 on the Castrate-resistant Prostate Cancer Market as compared to overall global economy.
  • Insight into the growth development strategies of major Castrate-resistant Prostate Cancer manufacturers and their key competitive landscape
  • Descriptive company profiles of the leading market participants, including Sanofi S.A., Pfizer Inc., Johnson & Johnson, Bayer AG, AstraZeneca plc, Dendreon Corporation, Clovis Oncology, Inc., and others.

Summary

Castration-Resistant Prostate Cancer (CRPC) commonly known as Hormone Refractory Prostate Cancer (CRPC), is a kind of prostate cancer which typically persists even after administering androgen deprivation therapy (ADT). The global CRPC market is primed to grow at a significant rate, owing to elevated unmet clinical need, growing prevalence rates, reduced survival benefits, and fast and better emerging treatment alterations.

The growth of the market would revolve around the innovative breakthrough treatments responsible for securing survival benefits. This would help in the penetration of the novel drugs in the market. There are mainly four types of treatment type for this type of cancer which includes, chemotherapy, hormonal therapy, radiation therapy, and immunotherapy.

In France, the incidence and prevalence of metastatic castration-resistant prostate cancer (mCRPC) were projected as 62 and 21 cases per 100,000 population. Furthermore, highest metastatic castration-resistant prostate cancer (mCRPC) incidence occurred in men having an age group of 80-89.

The Global Castrate-resistant Prostate Cancer Market was valued at $8.92 billion in 2020 and is expected to witness a steady growth at a CAGR of 8.17% during the forecast period.

  • Table 1 : Global Castrate-resistant Prostate Cancer Market, Through 2026
  • Table 2 : Global Castrate-resistant Prostate Cancer Market, by Treatment Type, Through 2026
  • Table 3 : Global Castrate-resistant Prostate Cancer Market, by Drug Delivery Method, Through 2026
  • Table 4 : Global Castrate-resistant Prostate Cancer Market, by End-User, Through 2026
  • Table 5 : Global Castrate-resistant Prostate Cancer Market, by Region, Through 2026
  • Table 6 : North America Castrate-resistant Prostate Cancer Market, by Treatment Type, Through 2026
  • Table 7 : North America Castrate-resistant Prostate Cancer Market, by Drug Delivery Method, Through 2026
  • Table 8 : North America Castrate-resistant Prostate Cancer Market, by End-User, Through 2026
  • Table 9 : North America Castrate-resistant Prostate Cancer Market, by Country, Through 2026
  • Table 10 : Europe Castrate-resistant Prostate Cancer Market, by Treatment Type, Through 2026
  • Table 11 : Europe Castrate-resistant Prostate Cancer Market, by Drug Delivery Method, Through 2026
  • Table 12 : Europe Castrate-resistant Prostate Cancer Market, by End-User, Through 2026
  • Table 13 : Europe Castrate-resistant Prostate Cancer Market, by Country, Through 2026
  • Table 14 : Asia-Pacific Castrate-resistant Prostate Cancer Market, by Treatment Type, Through 2026
  • Table 15 : Asia-Pacific Castrate-resistant Prostate Cancer Market, by Drug Delivery Method, Through 2026
  • Table 16 : Asia-Pacific Castrate-resistant Prostate Cancer Market, by End-User, Through 2026
  • Table 17 : Asia-Pacific Castrate-resistant Prostate Cancer Market, by Country, Through 2026
  • Table 18 : South America Castrate-resistant Prostate Cancer Market, by Treatment Type, Through 2026
  • Table 19 : South America Castrate-resistant Prostate Cancer Market, by Drug Delivery Method, Through 2026
  • Table 20 : South America Castrate-resistant Prostate Cancer Market, by End-User, Through 2026
  • Table 21 : South America Castrate-resistant Prostate Cancer Market, by Country, Through 2026
  • Table 22 : Middle East & Africa Castrate-resistant Prostate Cancer Market, by Treatment Type, Through 2026
  • Table 23 : Middle East & Africa Castrate-resistant Prostate Cancer Market, by Drug Delivery Method, Through 2026
  • Table 24 : Middle East & Africa Castrate-resistant Prostate Cancer Market, by End-User, Through 2026
  • Table 25 : Middle East & Africa Castrate-resistant Prostate Cancer Market, by Country, Through 2026
  • Table 26 : Sanofi S.A.: Financial Performance, Through 2020
  • Table 27 : Pfizer Inc.: Financial Performance, Through 2020
  • Table 28 : Johnson & Johnson: Financial Performance, Through 2020
  • Table 29 : Bayer AG: Financial Performance, Through 2020
  • Table 30 : AstraZeneca plc: Financial Performance, Through 2020
  • Table 31 : Dendreon Corporation: Financial Performance, Through 2020
  • Table 32 : Clovis Oncology, Inc.: Financial Performance, Through 2020
  • Table 33 : Astellas Pharma, Inc.: Financial Performance, Through 2020
  • Table 34 : Orion Corporation: Financial Performance, Through 2020
  • Table 35 : Kintor Pharmaceutical Limited: Financial Performance, Through 2020
  • Figure 1 : Global Castrate-resistant Prostate Cancer Market
  • Figure 2 : Global Castrate-resistant Prostate Cancer Market, by Value, 2019-2026
  • Figure 3 : Global Castrate-resistant Prostate Cancer Market, by Value, by Treatment Type, 2019-2026
  • Figure 4 : Global Castrate-resistant Prostate Cancer Market, by Value, by Drug Delivery Method, 2019-2026
  • Figure 5 : Global Castrate-resistant Prostate Cancer Market, by Value, by End-User, 2019-2026
  • Figure 6 : Global Castrate-resistant Prostate Cancer Market, by Value, by Region, 2020
  • Figure 7 : Global Castrate-resistant Prostate Cancer Market, by Value, by Company, 2020
  • Figure 8 : Global Castrate-resistant Prostate Cancer Market, Product Map, 2020
  • Figure 9 : North America Castrate-resistant Prostate Cancer Market, by Value, 2019-2026
  • Figure 10 : North America Castrate-resistant Prostate Cancer Market, by Value, by Treatment Type, 2019-2026
  • Figure 11 : North America Castrate-resistant Prostate Cancer Market, by Value, by Drug Delivery Method, 2019-2026
  • Figure 12 : North America Castrate-resistant Prostate Cancer Market, by Value, by End-User, 2019-2026
  • Figure 13 : North America Castrate-resistant Prostate Cancer Market, by Value, by Country, 2020
  • Figure 14 : Europe Castrate-resistant Prostate Cancer Market, by Value, 2019-2026
  • Figure 15 : Europe Castrate-resistant Prostate Cancer Market, by Value, by Treatment Type, 2019-2026
  • Figure 16 : Europe Castrate-resistant Prostate Cancer Market, by Value, by Drug Delivery Method, 2019-2026
  • Figure 17 : Europe Castrate-resistant Prostate Cancer Market, by Value, by End-User, 2019-2026
  • Figure 18 : Europe Castrate-resistant Prostate Cancer Market, by Value, by Country, 2020
  • Figure 19 : Asia-Pacific Castrate-resistant Prostate Cancer Market, by Value, 2019-2026
  • Figure 20 : Asia-Pacific Castrate-resistant Prostate Cancer Market, by Value, by Treatment Type, 2019-2026
  • Figure 21 : Asia-Pacific Castrate-resistant Prostate Cancer Market, by Value, by Drug Delivery Method, 2019-2026
  • Figure 22 : Asia-Pacific Castrate-resistant Prostate Cancer Market, by Value, by End-User, 2019-2026
  • Figure 23 : Asia-Pacific Castrate-resistant Prostate Cancer Market, by Value, by Country, 2020
  • Figure 24 : South America Castrate-resistant Prostate Cancer Market, by Value, 2019-2026
  • Figure 25 : South America Castrate-resistant Prostate Cancer Market, by Value, by Treatment Type, 2019-2026
  • Figure 26 : South America Castrate-resistant Prostate Cancer Market, by Value, by Drug Delivery Method, 2019-2026
  • Figure 27 : South America Castrate-resistant Prostate Cancer Market, by Value, by End-User, 2019-2026
  • Figure 28 : South America Castrate-resistant Prostate Cancer Market, by Value, by Country, 2020
  • Figure 29 : Middle East & Africa Castrate-resistant Prostate Cancer Market, by Value, 2019-2026
  • Figure 30 : Middle East & Africa Castrate-resistant Prostate Cancer Market, by Value, by Treatment Type, 2019-2026
  • Figure 31 : Middle East & Africa Castrate-resistant Prostate Cancer Market, by Value, by Drug Delivery Method, 2019-2026
  • Figure 32 : Middle East & Africa Castrate-resistant Prostate Cancer Market, by Value, by End-User, 2019-2026
  • Figure 33 : Middle East & Africa Castrate-resistant Prostate Cancer Market, by Value, by Country, 2020
  • Figure 34 : Sanofi S.A.: Revenue Share, 2020
  • Figure 35 : Pfizer Inc.: Revenue Share, 2020
  • Figure 36 : Johnson & Johnson: Revenue Share, 2020
  • Figure 37 : Bayer AG.: Revenue Share, 2020
  • Figure 38 : AstraZeneca plc: Revenue Share, 2020
  • Figure 39 : Dendreon Corporation: Revenue Share, 2020
  • Figure 40 : Clovis Oncology, Inc.: Revenue Share, 2020
  • Figure 41 : Astellas Pharma, Inc.: Revenue Share, 2020: Revenue Share, 2020
  • Figure 42 : Orion Corporation: Revenue Share, 2020
  • Figure 43 : Kintor Pharmaceutical Limited: Revenue Share, 2020

Market Research Studies is a North Carolina based, premier market research company. MRS brings over 50 years of market research publishing experience. Our reports cover a variety of industries such as Healthcare, Chemicals, Materials & Manufacturing, Research & Diagnostics, Environment & Sustainability, among others. Each year MRS releases hundreds of reports covering various topics. These reports are prepared by our in-house of team of Industry expert analysts. We strive to provide in-depth market analysis with accurate data to help our customers make informed decisions.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report